OP02: Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn’s disease patients stopping infliximabECCO’23 Copenhagen 2023
OP03: Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn’s disease patients: The EPIC-CD studyECCO’23 Copenhagen 2023
OP04: Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti-TNF-inadequate response patientsECCO’23 Copenhagen 2023
OP05: High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitisECCO’23 Copenhagen 2023
OP06: Multiomic interrogation of the epithelium in active Ulcerative Colitis reveals dysregulated myeloid cells associated with non-response to anti-Tumour Necrosis Factor therapy.ECCO’23 Copenhagen 2023
OP07: Absolute and relative risks of kidney and urological complications in patients with Inflammatory Bowel DiseaseECCO’23 Copenhagen 2023
OP08: Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trialECCO’23 Copenhagen 2023
OP09: Long-term Colectomy rates of Ulcerative Colitis over 40-year of Different Therapeutic eras – Results from a Western Hungarian Population-based Inception Cohort between 1977–2020ECCO’23 Copenhagen 2023
OP10: Proctocolectomy with permanent ileostomy is associated with better transplant-free survival in patients with primary sclerosing cholangitis: a retrospective cohort studyECCO’23 Copenhagen 2023
OP11: Ileocecal resection for recently diagnosed ileocecal Crohn’s disease is associated with improved long-term outcomes compared to anti-tumor necrosis factor therapy: a population-based study.ECCO’23 Copenhagen 2023
OP12: does early initiation of biologics change the natural history of IBD? a nationwide study from the epi-IIRNECCO’23 Copenhagen 2023
OP13: Postoperative Crohn’s disease recurrence: unanswered questions and future directions in diagnosis, pathophysiology, prevention and treatment. Conclusions from the 8th ECCO Scientific workshop.ECCO’23 Copenhagen 2023
OP14: Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIOECCO’23 Copenhagen 2023
OP15: Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extensionECCO’23 Copenhagen 2023
OP16: Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologicsECCO’23 Copenhagen 2023
OP17: Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional TherapiesECCO’23 Copenhagen 2023
OP18: Disease course of Crohn’s disease during the first ten years following diagnosis in a prospective European population-based inception cohort – the Epi-IBD cohortECCO’23 Copenhagen 2023
OP19: Gaps between ECCO quality standards of care and the real world: the E-QUALITY surveyECCO’23 Copenhagen 2023